Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Onchocerca volvulus | 0.0264 | 1 | 1 | |
Plasmodium vivax | SWIB/MDM2 domain-containing protein, putative | 0.0264 | 1 | 0.5 |
Brugia malayi | Peptidase family M28 containing protein | 0.0129 | 0.2059 | 0.2059 |
Trypanosoma cruzi | hypothetical protein, conserved | 0.0094 | 0 | 0.5 |
Plasmodium falciparum | SWIB/MDM2 domain-containing protein | 0.0264 | 1 | 1 |
Echinococcus multilocularis | Upstream activation factor subunit UAF30 | 0.0264 | 1 | 1 |
Chlamydia trachomatis | SWIB complex protein | 0.0264 | 1 | 0.5 |
Trypanosoma cruzi | Zn-finger in Ran binding protein and others, putative | 0.0094 | 0 | 0.5 |
Echinococcus granulosus | SWI:SNF matrix associated | 0.0264 | 1 | 1 |
Schistosoma mansoni | glutaminyl cyclase (M28 family) | 0.0129 | 0.2059 | 0.2059 |
Echinococcus multilocularis | SWI:SNF matrix associated | 0.0264 | 1 | 1 |
Trypanosoma cruzi | Zn-finger in Ran binding protein and others, putative | 0.0094 | 0 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0129 | 0.2059 | 0.2059 |
Toxoplasma gondii | SWIB/MDM2 domain-containing protein | 0.0264 | 1 | 1 |
Trypanosoma cruzi | mitochondrial RNA binding complex 1 subunit, putative | 0.0094 | 0 | 0.5 |
Leishmania major | hypothetical protein, conserved | 0.0094 | 0 | 0.5 |
Trypanosoma brucei | hypothetical protein, conserved | 0.0094 | 0 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0264 | 1 | 1 |
Schistosoma mansoni | brg-1 associated factor | 0.0264 | 1 | 1 |
Onchocerca volvulus | Glutaminyl cyclase homolog | 0.0129 | 0.2059 | 0.2059 |
Echinococcus granulosus | glutaminyl peptide cyclotransferase | 0.0129 | 0.2059 | 0.2059 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0264 | 1 | 0.5 |
Echinococcus granulosus | Upstream activation factor subunit UAF30 | 0.0264 | 1 | 1 |
Echinococcus multilocularis | SWI:SNF matrix associated | 0.0264 | 1 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0264 | 1 | 1 |
Trypanosoma brucei | mitochondrial RNA binding complex 1 subunit | 0.0094 | 0 | 0.5 |
Plasmodium vivax | hypothetical protein, conserved | 0.0264 | 1 | 0.5 |
Leishmania major | hypothetical protein, conserved | 0.0094 | 0 | 0.5 |
Trypanosoma cruzi | Zn-finger in Ran binding protein and others/FYVE zinc finger, putative | 0.0094 | 0 | 0.5 |
Leishmania major | hypothetical protein, conserved | 0.0094 | 0 | 0.5 |
Loa Loa (eye worm) | brahma associated protein | 0.0264 | 1 | 1 |
Trypanosoma cruzi | mitochondrial RNA binding complex 1 subunit, putative | 0.0094 | 0 | 0.5 |
Brugia malayi | brahma associated protein 60 kDa | 0.0264 | 1 | 1 |
Trypanosoma cruzi | WLM domain containing protein, putative | 0.0094 | 0 | 0.5 |
Leishmania major | hypothetical protein, conserved | 0.0094 | 0 | 0.5 |
Trypanosoma brucei | hypothetical protein, conserved | 0.0094 | 0 | 0.5 |
Chlamydia trachomatis | DNA topoisomerase I | 0.0264 | 1 | 0.5 |
Echinococcus multilocularis | SWI:SNF matrix associated | 0.0264 | 1 | 1 |
Trypanosoma cruzi | hypothetical protein, conserved | 0.0094 | 0 | 0.5 |
Brugia malayi | SWIB/MDM2 domain containing protein | 0.0264 | 1 | 1 |
Leishmania major | hypothetical protein, conserved | 0.0094 | 0 | 0.5 |
Plasmodium falciparum | SWIB/MDM2 domain-containing protein | 0.0264 | 1 | 1 |
Trypanosoma brucei | Zn-finger in Ran binding protein and others/FYVE zinc finger, putative | 0.0094 | 0 | 0.5 |
Toxoplasma gondii | DNA topoisomerase domain-containing protein | 0.0264 | 1 | 1 |
Trypanosoma cruzi | WLM domain containing protein, putative | 0.0094 | 0 | 0.5 |
Echinococcus multilocularis | glutaminyl peptide cyclotransferase | 0.0129 | 0.2059 | 0.2059 |
Loa Loa (eye worm) | SWIB/MDM2 domain-containing protein | 0.0264 | 1 | 1 |
Trypanosoma cruzi | hypothetical protein, conserved | 0.0094 | 0 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0264 | 1 | 1 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.